The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...

More than half of patients with fingernail psoriasis achieved complete fingernail clearance after 68 weeks of guselkumab treatment.

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, drugmaker Johnson & Johnson announced on Thursday. An interleukin (IL)-23 ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Janssen has filed its psoriasis injection guselkumab in the US, one of a crop of new drugs it hopes will each exceed $1 billion in sales. The Johnson & Johnson unit is seeking approval for ...

Your provider may also recommend biologics like Remicade (infliximab), Humira (adalimumab), Cosentyx (secukinumab), and Tremfya (guselkumab) for more severe cases of psoriasis. Another option is ...

Janssen’s Tremfya (guselkumab) psoriasis drug has been launched in the UK, where it hopes to steal sales from a crowd of well-established drugs such as Novartis’ Cosentyx. The launch in ...

claims-based cohort study that aimed to describe clinical and demographic characteristics of patients with psoriasis treated with biologics tildrakizumab, risankizumab, guselkumab, or ustekinumab.

US pharma major Johnson & Johnson (NYSE: JNJ) has won US approval for Tremfya (guselkumab) in the treatment of adults with ...